Retatrutide

Retatrutide (20mg) — Research Peptide

Retatrutide (LY3437943) at 20mg per vial provides the highest-dose format available for research into this triple GIP/GLP-1/glucagon receptor agonist. The 20mg format is suited to researchers requiring larger batch volumes, multi-arm dose-escalation protocols, or in vitro work requiring higher-concentration stock solutions of this Phase 3 investigational peptide.

Research Significance

As the first triple incretin agonist to enter Phase 3 clinical investigation, retatrutide represents a key research tool for investigators studying the differential contributions of GIP, GLP-1, and glucagon receptor signalling to metabolic outcomes. The additional glucagon receptor component — absent from both semaglutide and tirzepatide — makes retatrutide uniquely useful for delineating the specific hepatic and thermogenic contributions of GCGR signalling when combined with GLP-1R agonism.

The TRIUMPH Phase 3 programme includes dedicated trials in obesity (TRIUMPH-1), type 2 diabetes (TRIUMPH-2), cardiovascular outcomes (TRIUMPH-3), and MASH/NASH (TRIUMPH-NASH) — the broadest Phase 3 footprint of any peptide in the incretin class to date.

Product Specifications

• Peptide: Retatrutide (LY3437943)
• Dose: 20mg per vial
• Format: Lyophilised powder, bulk box of 10 vials
• Purity: ≥98% Janoshik HPLC verified
• Testing: Full COA — purity, sterility, endotoxin, heavy metals
• Storage: -20°C. Stable 24 months lyophilised.

For laboratory research use only. Not approved for human therapeutic use.